Impasse At US FDA Could Mean Stealth Abandons Barth Syndrome Treatment

 
• By Derrick Gingery
impasse
Stealth Biotherapeutics left a Type A meeting with the FDA not knowing what to do to push the elamipretide development program forward. • Source: Shutterstock

More from Rare Diseases

More from Pink Sheet